Nebulised interferon as a COVID-19 medicine

J. Tramper

Nebulised interferon as a COVID-19 medicine

Bio Process Engineering

Research output: Non-textual form › Web publication/site › Professional

Abstract

In a small clinical study conducted in April and May 2020, British scientists investigated the effect of inhalation of nebulised interferon-beta-1a (SNG001) on the development of COVID-19 in patients. The results are encouraging and justify further research.

Translated title of the contribution	Verneveld interferon als COVID-19 medicijn
Original language	English
Media of output	Online
Publication status	Published - 27 Dec 2020

Access to Document

https://www.biobasedpress.eu/2020/12/nebulised-interferon-as-a-covid-19-medicine/Licence: Publisher

Cite this

@misc{5efee29a82c848a5a979662314a2d169,

title = "Nebulised interferon as a COVID-19 medicine",

abstract = "In a small clinical study conducted in April and May 2020, British scientists investigated the effect of inhalation of nebulised interferon-beta-1a (SNG001) on the development of COVID-19 in patients. The results are encouraging and justify further research.",

author = "J. Tramper",

year = "2020",

month = dec,

day = "27",

language = "English",

}

TY - ADVS

T1 - Nebulised interferon as a COVID-19 medicine

AU - Tramper, J.

PY - 2020/12/27

Y1 - 2020/12/27

N2 - In a small clinical study conducted in April and May 2020, British scientists investigated the effect of inhalation of nebulised interferon-beta-1a (SNG001) on the development of COVID-19 in patients. The results are encouraging and justify further research.

AB - In a small clinical study conducted in April and May 2020, British scientists investigated the effect of inhalation of nebulised interferon-beta-1a (SNG001) on the development of COVID-19 in patients. The results are encouraging and justify further research.

M3 - Web publication/site

ER -

Nebulised interferon as a COVID-19 medicine

Abstract

Access to Document

Fingerprint

Cite this